HBIO logo

HBIO

Harvard Bioscience, Inc.NASDAQHealthcare
$5.20+6.35%ClosedMarket Cap: $23.3M

As of 2026-04-06

Valuation

View Details

P/E (TTM)

PEG

P/B

1.79

P/S

0.29

EV/EBITDA

11.36

DCF Value

$1.20

FCF Yield

20.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

53.0%

Operating Margin

-55.9%

Net Margin

-65.5%

ROE

-388.6%

ROA

-70.8%

ROIC

-80.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$23.7M$-2.8M$-0.64
FY 2025$86.5M$-56.7M$-12.80
Q3 2025$20.6M$-1.2M$-0.28
Q2 2025$20.4M$-2.3M$-0.52

Analyst Ratings

View All
BenchmarkSpeculative Buy
2026-03-16
BenchmarkSpeculative Buy
2025-09-10
BenchmarkSpeculative Buy
2025-05-13
KeybancSector Weight
2025-04-09

Trading Activity

Insider Trades

View All
Frost Mark Tofficer: Chief Financial Officer
SellWed Apr 01
Frost Mark Tofficer: Chief Financial Officer
BuyWed Apr 01
Duke John Ddirector, officer: Chief Executive Officer
SellMon Mar 23
Snider Williamdirector
BuyWed Mar 18
Snider Williamdirector
BuyWed Mar 18

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NASDAQ

Beta

1.50

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Peers